On Nov 15, major Wall Street analysts update their ratings for $Tarsus Pharmaceuticals (TARS.US)$, with price targets ranging from $65 to $84.
BofA Securities analyst Jason Gerberry maintains with a buy rating, and maintains the target price at $68.
Oppenheimer analyst Francois Brisebois maintains with a buy rating, and adjusts the target price from $63 to $65.
H.C. Wainwright analyst Oren Livnat maintains with a buy rating, and adjusts the target price from $61 to $73.
LifeSci Capital analyst Cory Jubinville, PhD maintains with a buy rating, and adjusts the target price from $67 to $84.
Furthermore, according to the comprehensive report, the opinions of $Tarsus Pharmaceuticals (TARS.US)$'s main analysts recently are as follows:
Tarsus Pharmaceuticals' third-quarter EPS exceeded expectations, with a significant beat on Xdemvy net product sales reaching $48.1M, though the number of vials dispensed aligned with forecasts. The company's discussion during the call was centered on a more positive forecast for Xdemvy in the fourth quarter and subsequent periods, following the expansion of the sales team.
Tarsus Pharmaceuticals reported a third-quarter topline of $48.1M, surpassing both the anticipated $44.3M and the consensus estimate of $43M, showcasing a robust growth of 40%. The company's advancements with target ECPs are noteworthy, with over 13,000 ECPs already prescribing Xdemvy. It's expected that Tarsus' efforts will continue to propel Xdemvy's growth. Positive data concerning MGD has been met with enthusiasm, and there is an anticipation for the company's strategic approach to commercialization.
Here are the latest investment ratings and price targets for $Tarsus Pharmaceuticals (TARS.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月15日，多家华尔街大行更新了$Tarsus Pharmaceuticals (TARS.US)$的评级，目标价介于65美元至84美元。
美银证券分析师Jason Gerberry维持买入评级，维持目标价68美元。
奥本海默控股分析师Francois Brisebois维持买入评级，并将目标价从63美元上调至65美元。
H.C. Wainwright分析师Oren Livnat维持买入评级，并将目标价从61美元上调至73美元。
LifeSci Capital分析师Cory Jubinville, PhD维持买入评级，并将目标价从67美元上调至84美元。
此外，综合报道，$Tarsus Pharmaceuticals (TARS.US)$近期主要分析师观点如下：
tarsus pharmaceuticals的第三季度每股收益超出预期，Xdemvy的净产品销售额达到4810万%，尽管分发的瓶装数量与预期一致。公司在看涨期间的讨论集中于对Xdemvy在第四季度及后续时期的更积极预期，这得益于销售团队的扩张。
tarsus pharmaceuticals报告的第三季度总收入为4810万%，超过预期的4430万%和共识预估的4300万%，显示出40%的强劲增长。公司在目标ECP方面的进展值得注意，目前已有超过13,000名ECP在开处方Xdemvy。预计tarsus的努力将继续推动Xdemvy的增长。有关MGD的积极数据受到热烈欢迎，人们期待公司在商业化方面的战略方法。
以下为今日4位分析师对$Tarsus Pharmaceuticals (TARS.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
